Source: Healio News
Novel therapies and treatment strategies could help to address the clinical challenges of triple-class refractory multiple myeloma, according to a speaker at Chemotherapy Foundation Symposium.
“Triple-class refractory multiple myeloma is kind of the all-equalizer because it tells us where the patient is in terms of sensitivity or refractoriness to prior therapies,” Noa Biran, MD, of the multiple myeloma division at Hackensack Meridian John Theurer Cancer Center, said during her presentation.
The subgroup includes patients who experience disease progression while on or within 60 days